Patenting Risk Evaluation & Mitigation Strategies; For Pharmaceuticals: A New Life Cycle Management Target for Patents?
January 2, 2009
Foley Partners Stephen Maebius, Judith Waltz, David Rosen and Associate Sean Tu authored an article titled “Patenting Risk Evaluation & Mitigation Strategies; For Pharmaceuticals: A New Life Cycle Management Target for Patents?” in the January 2, 2009 issue of BNA’s Pharmaceutical Law & Industry Report.
Reproduced with permission from BNA’s Pharmaceutical Law & Industry Report, by The Bureau of National Affairs, Inc. http://www.bna.com.
Author(s)
Related Insights
July 9, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 9, 2025
Energy Current
ITC and PTC Changes Under the Big Beautiful Bill Act
President Trump last week signed into law the One Big Beautiful Bill Act (the “Act”). The Act made a number of changes to the clean…
July 9, 2025
Powered by Foley
Energy Industry Disputes
Whether we like it or not, there’s always a chance a dispute will arise during the lifespan of an energy project, which may only accelerate following changes to federal energy tax credits that could significantly upend parties’ commercial assumptions.